Esco Lifesciences, a Singapore-based provider of life sciences tools and services, closed a US$200m Series A and Crossover round.
The round was led by Vivo Capital and Novo Holdings A/S, with participation from new investors China Investment Corporation, Singapore-based global investor EDBI and other investors.
The company intends to use the funds to create an innovation hub in Boston, focused on cell and gene therapy tools and technologies, increase R&D and in-licensing efforts to develop and commercialize novel life science research tools in emerging domains.
Led by XQ Lin, Chairman and CEO, Esco Lifesciences provides enabling technologies, products and services to the life sciences and healthcare industries, supporting academic research and scientific discoveries, clinical practice, as well as biopharmaceutical R&D and manufacturing. The company has an extensive sales network in over 100 countries, direct sales and service offices in over 20 countries, 8 manufacturing and R&D hubs in the US, Europe, the UK, China, Singapore, and over 1300 employees worldwide.